Revenue Update on RedHill Biopharma Ltd – ADR(NASDAQ:RDHL)

RedHill Biopharma Ltd – ADR(NASDAQ:RDHL) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Jul 26, 2016. Earnings per share were $-0.06. Analysts had estimated an EPS of $-0.58.

RedHill Biopharma Ltd – ADR (RDHL) made into the market gainers list on Fridays trading session with the shares advancing 3.39% or 0.43 points. Due to strong positive momentum, the stock ended at $13.13, which is also near the day’s high of $13.13. The stock began the session at $12.7 and the volume stood at 28,089 shares. The 52-week high of the shares is $15.63 and the 52 week low is $8.1. The company has a current market capitalization of $167 M and it has 1,27,11,429 shares in outstanding.

RedHill Biopharma Ltd. is a biopharmaceutical company primarily focused on the development of late clinical-stage orally-administered small molecule drugs for the treatment of inflammatory and gastrointestinal diseases including gastrointestinal cancers. The Company’s pipeline of products includes RHB-105 RHB-104 BEKINDA (RHB-102) RHB-106 ABC294640 MESUPRON RP101 and RIZAPORT (RHB-103).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

RedHill Biopharma Ltd - ADR - Is it time to Sell?

Top Brokerage Firms are advising their investors on RedHill Biopharma Ltd - ADR. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.